Grants for Public and State controlled institutions of higher education - Federal

The purpose of this SAMHSA program is to prevent and reduce alcohol use among youth and young adults ages 12-20 in communities throughout the United States. The program aims to: (1) address norms regarding alcohol use by youth, (2) reduce opportunities for underage drinking, (3) create changes in underage drinking enforcement efforts, (4) address penalties for underage use, and/or (5) reduce negative consequences associated with underage drinking (e.g., motor vehicle crashes, sexual assaults). In addition, applicants will build on strategic plans that were developed under a Drug Free Communities (DFC) grant.

This funding opportunity provides up to $1.3 billion to support the development and demonstration of advanced carbon capture technologies for power generation and industrial sectors, targeting a wide range of eligible applicants including educational institutions, nonprofits, and businesses.

This funding opportunity supports U.S. higher education institutions and nonprofits in training predoctoral and postdoctoral researchers to advance interdisciplinary research on Alzheimer's Disease and related dementias.

This funding opportunity supports early-career researchers from diverse backgrounds in advancing their studies on Alzheimer's Disease-Related Dementias, helping them transition from mentored postdoctoral positions to independent faculty roles.

This funding opportunity supports conservation projects for at-risk species in the U.S. by providing financial assistance to a diverse range of applicants, including nonprofits, educational institutions, and government entities, to implement proactive measures that prevent species from needing federal protection.

This funding opportunity provides financial support to local governments, educational institutions, tribal governments, and nonprofit organizations in Colorado for projects aimed at reducing wildfire risks and enhancing community resilience against wildfires.

This grant provides funding to organizations that support programs helping older adults and individuals with disabilities manage chronic diseases while improving their behavioral health through education and community partnerships.

This funding opportunity provides financial support for small-scale biomedical research projects at institutions with limited NIH funding, focusing on enhancing research experiences for health professional, undergraduate, and graduate students.

The Embassy of the United States of America in New Delhi announces an open competition to implement a project to increase Indian engagement as a regional leader with like-minded partners across the Indo-Pacific. This will be accomplished via a three -day residency in India for 15 established opinion leaders (EOLs) from the think tank space in the United States, Japan, Australia, South Asia, and Southeast Asia along with 15 counterparts from India. Please follow all instructions below.By March 2025, 15 EOL think tankers from participating countries will demonstrate a recognized attitude shift and perspective/behavior change toward the United States, make data-informed decisions as evidenced by writing at least 15 joint research papers/articles on regional cooperation and best practices in the Indo-Pacific under varied Indo-Pacific Strategy Pillars. The selected grantee will endeavor to have these papers/articles published in global journals and media including those published in participating countries to better inform stakeholders and impact policymaking focused on tackling defined challenges in the Indo-Pacific region.(Please refer to the full announcement available under 'related documents' tab)

NASA has released a Research Announcement for the Human Exploration Research Opportunities (HERO) program, inviting U.S. institutions to submit proposals for applied research projects aimed at enhancing human health and performance for space exploration, with grants ranging from under $100K to $1.2M per year, for a period of one to five years.

The National Institutes of Health (NIH) Institutes and Centers (ICs) intend to reissue a Notice of Funding Opportunity (NOFO) to continue the Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed) program. The full list of participating ICs will be available in the published NOFO. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive applications. The NOFO is anticipated to be published in Spring 2024 with an expected first application due date in Summer 2024. The NOFO will utilize the R15 activity code. Pertinent details of the planned NOFO are provided below.

This program provides funding to public bodies, nonprofit organizations, and government entities to support economic development and job creation initiatives in rural areas with populations under 50,000.

This funding opportunity provides financial support to organizations working to improve community health services in Liberia, focusing on maternal and child health, nutrition, and disease prevention in underserved areas.

This award is to support community development and resilience with geospatial data and digital technology by engaging university-aged youth. The activities anticipated as part of this award will add valuable, free and openly accessible data to digital ecosystems of lower and middle income countries, which in turn can be used by USAID programs and humanitarian assistance activities. The award will specifically focus on youth training, geospatial data collection, and analysis to help communities address local development challenges. Activities will also engage marginalized populations to ensure representation of the diversity of partner country populations. USAID anticipates awarding one to three grants and/or cooperative agreements under this Addendum. Issuance of this Addendum does not constitute an award or commitment on the part of the U.S. Government to make an award, nor does it commit the U.S. Government to pay for costs incurred in the preparation and submission of a Concept Note or Application(s). The actual number of assistance awards is subject to the availability of funds, as well as the viability of eventual full Applications received.

To aid BOEMs ongoing modeling efforts, this study aims to develop a near real-time (NRT) modeling system for the endangered North Atlantic right whale population and a survey segment database of cetacean and other marine wildlife observations. The modeling system will predict whale density across the eastern seaboard using real-time visual and acoustic observations, coupled with environmental covariates.The study objectives are to integrate various survey datasets, including aerial and ship surveys, into a segment database and develop NRT models that can respond more quickly and flexibly to shifts in species space use and phenology. BOEM and the National Marine Fisheries Service will fund this study jointly.Initially, the system will serve as a research and development testbed, allowing a collaborative team of developers to address statistical challenges and refine software workflow. After the effectiveness of the density models has been established, daily predictions will be made operational and disseminated to the public. The system's capabilities could be expanded to issue short-term forecasts and encompass additional species, contingent on data availability and the development of suitable methods.

This grant seeks innovative proposals from a wide range of organizations, including universities and small businesses, to develop advanced technologies that enhance national defense capabilities.

This grant provides funding and mentorship for early-career researchers to advance their work in health issues related to individuals affected by the 9/11 attacks, focusing on improving diagnosis and treatment for this population.

The "Individually Measured Phenotypes to Advance Computational Translation in Mental Health (IMPACT-MH)" grant aims to support research that develops new behavioral measures and data infrastructure to improve the diagnosis, prognosis, and treatment of mental disorders.

This Notice of Funding Opportunity (NOFO) requests applications to explore human pancreatic tissues and the immune compartment for the discovery of specific signaling or processing pathways that may contribute to the asymptomatic phase of T1D, the discovery of early biomarkers of T1D pathogenesis, the development of diagnostic tools for the detection and staging of early T1D in at-risk or recently-diagnosed individuals, and/or the identification and biological validation of therapeutic targets for the development of preventative or early treatment strategies. Successful applicants will join the Consortium on Beta Cell Death and Survival (CBDS), whose mission is to better define and detect the mechanisms of beta cell stress and destruction central to the development of T1D in humans, with the long-term goal of protecting the residual beta cell mass in T1D patients as early as possible in the disease process, and of preventing the progression to autoimmunity. The CBDS is part of a collaborative research framework, the Human Islet Research Network (HIRN, https://hirnetwork.org/), whose overall mission is to support innovative and collaborative translational research to understand how human beta cells are lost in T1D, and to find innovative strategies to protect and replace functional beta cell mass in humans. This NOFO will only support studies with a primary focus on increasing our understanding of human disease biology (as opposed to rodent or other animal models). This NOFO will not accept applications proposing a clinical trial.

Notice of Funding Opportunity Description Background The Food and Drug Administration (FDA) protects the public health by ensuring that medical products intended to be marketed in the United States are safe and effective for their intended use. FDA stakeholders are exploring innovative ways to produce scientific evidence in support of regulatory submissions, including the development of new data sources, study designs, methodologies, and technologies. FDA encourages and facilitates the use of such innovative approaches while ensuring that the scientific evidence supporting marketing approvals meet our high evidentiary standards. The Prescription Drug User Fee Act VII (PDUFA VII) commitment letter represents the product of discussions between the FDA, regulated industry, and public stakeholders, as mandated by Congress. The performance and procedural goals and other commitments specified in the PDUFA VII commitment letter apply to aspects of the human drug review program that are important for facilitating timely access to safe, effective, and innovative new medicines for patients. The commitment letter includes goals relating to the use of digital health technologies (DHTs) to support drug development and review. A DHT is a system that uses computing platforms, connectivity, software, and/or sensors, for health care and related uses. DHTs for remote data acquisition in clinical investigations can include hardware and/or software to perform one or more functions. DHTs may rely on or work with other technologies that support their operation, such as general-purpose computing platforms (e.g., smartphones) and communication networks. Among other activities relating to the use of DHTs, FDA has established a Framework for the Use of DHTs in Drug and Biological Product Development to guide the use of DHT-derived data in regulatory decision-making for drugs (hereinafter Framework ). The Framework highlights FDA’s DHT efforts including workshops and demonstration projects; engagement with stakeholders; establishment of internal processes to support the evaluation of DHTs for use in drug development; promotion of shared learning and consistency regarding DHT-based policy, procedure, and analytic tool development; and publication of guidance documents. In addition, FDA’s webpage DHTs for Drug Development (available at: https://www.fda.gov/science-research/science-and-research-special-topics/digital-health-technologies-dhts-drug-development) provides an overview of the ongoing DHT efforts, including demonstration projects. A variety of project types are welcomed under this NOFO, applicable to drugs and biologics (not devices). FDA is particularly interested in projects that evaluate the use of DHTs in drug development. Project Objectives The overarching goal of this notice of funding opportunity (NOFO) is to explore the role of DHTs (e.g., actigraphy, photography, environmental sensors) in the evaluation of new drugs. These projects may involve engagement with researchers from academia, the biopharmaceutical industry, patient groups, and other stakeholders. The objectives of these projects are to advance DHTs for clinical drug development, expand the ability to capture early manifestations of chronic diseases, determine outcomes in populations with unmet medical needs and enhance convenience for trial participants by allowing for remote data acquisition in clinical investigations. The scope includes, but is not limited to, projects that focus on: Comparing digital measurements to traditional measurements in clinical trials to evaluate drugs Developing and evaluating novel endpoints using DHTs to address unmet needs for drug clinical trials (e.g., use of environmental sensors to capture apnea in pediatric patients) Comparing metrics to evaluate continuous measurements (e.g., maximum activity and stamina) Capturing early manifestations of chronic diseases (e.g., dementia) through the use of DHTs